In vivo DA D1 receptor selectivity of NNC 112 and SCH 23390

Molecular Imaging and Biology

Volumn 9, Issue 3, 2007, Pages 117-125

  Ekelund, Jesper ^a,b   Slifstein, Mark ^a   Narendran, Raj ^a   Guillin, Olivier ^b   Belani, Hemant ^b   Guo, Ning Ning ^a,b   Hwang, Yuying ^a,b   Hwang, Dah Ren ^a,b   Abi Dargham, Anissa ^a,b   Laruelle, Marc ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

Dopamine D1 receptor; In vivo selectivity; NNC 112; Position emission tomography; SCH 23390; Serotonin 2A receptor

Indexed keywords

5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE C 11; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL C 11; DOPAMINE 1 RECEPTOR; RADIOPHARMACEUTICAL AGENT; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BABOON; BRAIN CORTEX; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; IN VIVO STUDY; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ANIMALS; BENZAZEPINES; BENZOFURANS; CARBON RADIOISOTOPES; KINETICS; MALE; PAPIO; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1;

PAPIO;

EID: 34248211258     PISSN: 15361632     EISSN: 18602002     Source Type: Journal    
DOI: 10.1007/s11307-007-0077-4     Document Type: Article

References (60)

1. Meador-Woodruff JH, et al. (1996) Dopamine receptor mRNA expression in human striatum and neocortex. Neuropsychopharmacology 15:17-29
2. Arnsten AF, et al. (1994) Dopamine D1 receptor mechanisms in the cognitive performance of young adult and aged monkeys. Psychopharmacology (Berl) 116:143-151
3. Sawaguchi T, Goldman-Rakic PS (1994) The role of D1-dopamine receptor in working memory: Local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 71:515-528
4. Williams GV, Goldman-Rakic PS (1995) Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376:572-575
5. Bernabeu R, et al. (1997) Involvement of hippocampal cAMP/cAMP-dependent protein kinase signaling pathways in a late memory consolidation phase of aversively motivated learning in rats. Proc Natl Acad Sci U S A 94:7041-7046
6. Huang YY, Kandel ER (1995) D1/D5 receptor agonists induce a protein synthesis-dependent late potentiation in the CA1 region of the hippocampus. Proc Natl Acad Sci U S A 92:2446-2450
7. Otmakhova NA, Lisman JE (1996) D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 16:7478-7486
8. Seamans JK, Floresco SB, Phillips AG (1998) D1 receptor modulation of hippocampal-prefrontal cortical circuits integrating spatial memory with executive functions in the rat. J Neurosci 18:1613-1621
9. Davis KL, et al. (1991) Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486
10. Goldman-Rakic PS, Muly EC III, Williams GV (2000) D(1) receptors in prefrontal cells and circuits. Brain Res Brain Res Rev 31:295-301
11. Weinberger DR (1987) Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 44:660-669
12. Andersen PH, Gronvald FC, Jansen JA (1985) A comparison between dopamine-stimulated adenylate cyclase and 3H-SCH 23390 binding in rat striatum. Life Sci 37:1971-1983
13. Billard W, et al. (1984) Characterization of the binding of 3H-SCH 23390, a selective D-1 receptor antagonist ligand, in rat striatum. Life Sci 35:1885-1893
14. Farde L, et al. (1987) PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology (Berl) 92:278-284
15. Halldin C, et al. (1986) Preparation of 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 37:1039-1043
16. Chan GL, et al. (1998) Reproducibility of the distribution of carbon-11-SCH 23390, a dopamine D1 receptor tracer, in normal subjects. J Nucl Med 39:792-797
17. Laihinen AO, et al. (1994) PET studies on dopamine D1 receptors in the human brain with carbon-11-SCH 39166 and carbon-11-NNC 756. J Nucl Med 35:1916-1920
18. Karlsson P, et al. (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159:761-767
19. De Keyser J, et al. (1988) Autoradiographic localization of D1 and D2 dopamine receptors in the human brain. Neurosci Lett 91:142-147
20. Hall H, et al. (1994) Distribution of D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain. Neuropsychopharmacology 11:245-256
21. Laruelle M, et al. (1991) Characterization of [125I]SCH 23982 binding in human brain: Comparison with [3H]SCH 23390. Neurosci Lett 131:273-276
22. Hirvonen J, et al. (2001) Measurement of cortical dopamine d1 receptor binding with 11C[SCH23390]: A test-retest analysis. J Cereb Blood Flow Metab 21:1146-1150
23. Andersen PH, et al. (1992) NNC-112, NNC-687 and NNC-756, new selective and highly potent dopamine D1 receptor antagonists. Eur J Pharmacol 219:45-52
24. Abi-Dargham A, et al. (1999) PET studies of binding competition between endogenous dopamine and the D1 radiotracer [11C]NNC 756. Synapse 32:93-109
25. Halldin C, et al. (1993) [11C]NNC 687 and [11C]NNC 756, dopamine D-1 receptor ligands. Preparation, autoradiography and PET investigation in monkey. Nucl Med Biol 20:945-953
26. Halldin C, et al. (1998) Carbon-11-NNC 112: A radioligand for PET examination of striatal and neocortical D1-dopamine receptors. J Nucl Med 39:2061-2068
27. Karlsson P, et al. (1993) PET examination of [11C]NNC 687 and [11C]NNC 756 as new radioligands for the D1-dopamine receptor. Psychopharmacology (Berl) 113:149-156
28. Abi-Dargham A, et al. (2000) Measurement of striatal and extrastriatal dopamine D1 receptor binding potential with [11C]NNC 112 in humans: validation and reproducibility. J Cereb Blood Flow Metab 20:225-243
29. Okubo Y, et al. (1997) Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET. Nature 385:634-636
30. Abi-Dargham A, et al. (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22:3708-3719
31. Abi-Dargham A, Moore H (2003) Prefrontal DA transmission at D1 receptors and the pathology of schizophrenia. Neuroscientist 9:404-416
32. Guo N, et al. (2003) Dopamine depletion and in vivo binding of PET D1 receptor radioligands: Implications for imaging studies in schizophrenia. Neuropsychopharmacology 28:1703-1711
33. Lidow MS, et al. (1989) Distribution of major neurotransmitter receptors in the motor and somatosensory cortex of the rhesus monkey. Neuroscience 32:609-627
34. Suhara T, et al. (1992) D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl) 106:14-18
35. Brix G, et al. (1997) Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 38:1614-1623
36. Riche D, et al. (1988) Anatomical atlas of the baboon's brain in the orbito-meatal plane used in experimental positron emission tomography. Brain Res Bull 20:283-301
37. Woods RP, Mazziotta JC, Cherry SR (1993) MRI-PET registration with automated algorithm. J Comput Assist Tomogr 17:536-546
38. Mintun MA, et al. (1984) A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 15:217-227
39. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
40. Laruelle M, et al. (1994) SPECT quantification of [123I]iomazenil binding to benzodiazepine receptors in nonhuman primates: II. Equilibrium analysis of constant infusion experiments and correlation with in vitro parameters. J Cereb Blood Flow Metab 14:453-465
41. Watabe H, et al. (2000) Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab 20:899-909
42. Frankle WG, et al. (2006) Estimation of serotonin transporter parameters with C-11-DASB in healthy humans: Reproducibility and comparison of methods. J Nucl Med 47:815-826
43. Gunn RN, et al. (1998) Tracer kinetic modeling of the 5-HT1A receptor ligand [carbonyl-11C]WAY-100635 for PET. Neuroimage 8:426-440
44. Parsey RV, et al. (1998) Kinetic derivation of serotonin 5HT-1A receptor binding potential with [11C]carbonyl-way 100635 and competition studies with endogenous serotonin. Neuroimage 7:A10
45. Chou YH, Halldin C, Farde L (2006) Clozapine binds preferentially to cortical D-1-like dopamine receptors in the primate brain: A PET study. Psychopharmacology 185:29-35
46. Schotte A, et al. (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73
47. Chipkin RE, et al. (1988) Pharmacological profile of SCH39166: A dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. J Pharmacol Exp Ther 247:1093-1102
48. Bogeso KP, et al. (1995) Enhanced D1 affinity in a series of piperazine ring substituted 1-piperazino-3-arylindans with potential atypical antipsychotic activity. J Med Chem 38:4380-4392
49. Markstein R, Hoyer D, Engel G. (1986) 5-HT1A-receptors mediate stimulation of adenylate cyclase in rat hippocampus. Naunyn Schmiedebergs Arch Pharmacol 333:335-341
50. Roth BL, Ciaranello RD, Meltzer HY (1992) Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 260:1361-1365
51. Neumeyer JL, et al. (2003) Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 474:137-140
52. Sunahara RK, et al. (1991) Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1. Nature 350:614-619
53. Andersen PH (1988) Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur J Pharmacol 146:113-120
54. Lawler CP, et al. (1999) Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. Neuropsychopharmacology 20:612-627
55. Watts VJ, et al. (1993) Dopamine D1 receptors: Efficacy of full (dihydrexidine) vs. partial (SKF38393) agonists in primates vs. rodents. Eur J Pharmacol 242:165-172
56. Borsini F, et al. (1995) BIMT 17, a 5-HT2A receptor antagonist and 5-HT1A receptor full agonist in rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 352:276-282
57. Mottola DM, et al. (2002) Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase. J Pharmacol Exp Ther 301:1166-1178
58. Bymaster FP, et al. (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophr Res 37:107-122
59. Barrett RJ, et al. (1993) in vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): A selective, orally active A1 adenosine receptor antagonist. J Pharmacol Exp Ther 265:227-236
60. Simonneaux V, Murrin LC, Ebadi M (1990) Characterization of D1 dopamine receptors in the bovine pineal gland with [3H]SCH 23390. J Pharmacol Exp Ther 253:214-220